



Alkermes' Corporate Presentation to be Webcast at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

January 29, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2008--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Merrill Lynch on Tuesday, February 5, 2008 at 4:00 p.m. EST. The presentation will be webcast from The Grand Hyatt Hotel in New York and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease. Alkermes manufactures RISPERDAL(R) CONSTA(R), marketed by Janssen-Cilag (Janssen, L.P.), a wholly owned division of Johnson & Johnson, and developed and manufactures VIVITROL(R), marketed in the U.S. primarily by Cephalon, Inc. The company's pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Alkermes is headquartered in Cambridge, Massachusetts, with research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications

SOURCE: Alkermes, Inc.